ATE363292T1 - Hydrogelzusammensetzungen mit kontrollierter freigabe von wachstumsfaktoren - Google Patents

Hydrogelzusammensetzungen mit kontrollierter freigabe von wachstumsfaktoren

Info

Publication number
ATE363292T1
ATE363292T1 AT99946759T AT99946759T ATE363292T1 AT E363292 T1 ATE363292 T1 AT E363292T1 AT 99946759 T AT99946759 T AT 99946759T AT 99946759 T AT99946759 T AT 99946759T AT E363292 T1 ATE363292 T1 AT E363292T1
Authority
AT
Austria
Prior art keywords
controlled release
growth factors
hydrogel compositions
compositions
physiologically acceptable
Prior art date
Application number
AT99946759T
Other languages
English (en)
Inventor
Robert Jennings
Bing Yang
Andrew Protter
Yu-Chang Wang
Original Assignee
Scios Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scios Inc filed Critical Scios Inc
Application granted granted Critical
Publication of ATE363292T1 publication Critical patent/ATE363292T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT99946759T 1998-09-04 1999-09-03 Hydrogelzusammensetzungen mit kontrollierter freigabe von wachstumsfaktoren ATE363292T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9916898P 1998-09-04 1998-09-04

Publications (1)

Publication Number Publication Date
ATE363292T1 true ATE363292T1 (de) 2007-06-15

Family

ID=22273280

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99946759T ATE363292T1 (de) 1998-09-04 1999-09-03 Hydrogelzusammensetzungen mit kontrollierter freigabe von wachstumsfaktoren

Country Status (13)

Country Link
US (1) US6331309B1 (de)
EP (1) EP1107791B8 (de)
JP (2) JP2002524425A (de)
AT (1) ATE363292T1 (de)
AU (1) AU758178B2 (de)
CA (1) CA2341410C (de)
CY (1) CY1107704T1 (de)
DE (1) DE69936212T2 (de)
DK (1) DK1107791T3 (de)
ES (1) ES2288024T3 (de)
IL (2) IL141688A0 (de)
PT (1) PT1107791E (de)
WO (1) WO2000013710A2 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE314863T1 (de) * 1999-04-22 2006-02-15 Eidgenoess Tech Hochschule Kontrollierte abgabe der wachstumsfaktoren von heparin enthaltenden matrizen
US20020013261A1 (en) * 2000-05-18 2002-01-31 Robert Pawliuk Methods and compositions for promoting angiogenesis using polyethylene glycol (PEG) polymers
AR034517A1 (es) * 2001-06-21 2004-02-25 Astrazeneca Ab Formulacion farmaceutica
US6818613B2 (en) 2001-11-07 2004-11-16 Ortho-Mcneil Pharmaceutical, Inc. Aqueous sustained-release formulations of proteins
WO2003054146A2 (en) 2001-11-14 2003-07-03 Northwestern University Self-assembly and mineralization of peptide-amphiphile nanofibers
US8608661B1 (en) 2001-11-30 2013-12-17 Advanced Cardiovascular Systems, Inc. Method for intravascular delivery of a treatment agent beyond a blood vessel wall
JP2003238439A (ja) * 2002-02-13 2003-08-27 Yasuhiko Tabata 虚血治療剤
AU2003215280A1 (en) 2002-02-15 2003-09-09 Northwestern University Self-assembly of peptide-amphiphile nanofibers under physiological conditions
US20030203032A1 (en) * 2002-04-25 2003-10-30 Schultz Clyde L. Growth factor delivery system for the healing of wounds and the prevention of inflammation and disease
JP2005529122A (ja) * 2002-04-25 2005-09-29 ラピッドヒール インコーポレイティッド 創傷治癒のための増殖因子送達システムならびに炎症および疾患の予防方法
SE0201661D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab New salts
SE0201659D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab Modified release pharmaceutical formulation
US7361368B2 (en) 2002-06-28 2008-04-22 Advanced Cardiovascular Systems, Inc. Device and method for combining a treatment agent and a gel
WO2004018628A2 (en) 2002-08-21 2004-03-04 Northwestern University Charged peptide-amphiphile solutions & self-assembled peptide nanofiber networks formed therefrom
JP2004115413A (ja) * 2002-09-25 2004-04-15 Yasuhiko Tabata 冠状動脈狭窄または閉塞治療用徐放性製剤
US7554021B2 (en) 2002-11-12 2009-06-30 Northwestern University Composition and method for self-assembly and mineralization of peptide amphiphiles
US7683025B2 (en) 2002-11-14 2010-03-23 Northwestern University Synthesis and self-assembly of ABC triblock bola peptide amphiphiles
WO2004072104A2 (en) 2003-02-11 2004-08-26 Northwestern University Methods and materials for nanocrystalline surface coatings and attachment of peptide amphiphile nanofibers thereon
US20050074497A1 (en) * 2003-04-09 2005-04-07 Schultz Clyde L. Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
US20050255144A1 (en) * 2003-04-09 2005-11-17 Directcontact Llc Methods and articles for the delivery of medicaments to the eye for the treatment of posterior segment diseases
US9216106B2 (en) 2003-04-09 2015-12-22 Directcontact Llc Device and method for the delivery of drugs for the treatment of posterior segment disease
US8038991B1 (en) 2003-04-15 2011-10-18 Abbott Cardiovascular Systems Inc. High-viscosity hyaluronic acid compositions to treat myocardial conditions
US7641643B2 (en) 2003-04-15 2010-01-05 Abbott Cardiovascular Systems Inc. Methods and compositions to treat myocardial conditions
US8821473B2 (en) 2003-04-15 2014-09-02 Abbott Cardiovascular Systems Inc. Methods and compositions to treat myocardial conditions
WO2005056576A2 (en) 2003-12-05 2005-06-23 Northwestern University Branched peptide amphiphiles, related epitope compounds and self assembled structures thereof
KR20070004560A (ko) 2003-12-05 2007-01-09 노오쓰웨스턴 유니버시티 성장 인자 전달을 위한 자가조립 펩티드 친양매성 화합물들및 관련 방법들
CA2588449A1 (en) * 2004-11-24 2006-06-01 Therakine Corporation An implant for intraocular drug delivery
KR20070108555A (ko) 2005-03-04 2007-11-12 노오쓰웨스턴 유니버시티 혈관신생 헤파린 결합 펩티드 양친매성 화합물
US20080125745A1 (en) 2005-04-19 2008-05-29 Shubhayu Basu Methods and compositions for treating post-cardial infarction damage
US8828433B2 (en) 2005-04-19 2014-09-09 Advanced Cardiovascular Systems, Inc. Hydrogel bioscaffoldings and biomedical device coatings
US9539410B2 (en) 2005-04-19 2017-01-10 Abbott Cardiovascular Systems Inc. Methods and compositions for treating post-cardial infarction damage
US7732190B2 (en) 2006-07-31 2010-06-08 Advanced Cardiovascular Systems, Inc. Modified two-component gelation systems, methods of use and methods of manufacture
US9242005B1 (en) 2006-08-21 2016-01-26 Abbott Cardiovascular Systems Inc. Pro-healing agent formulation compositions, methods and treatments
US8741326B2 (en) 2006-11-17 2014-06-03 Abbott Cardiovascular Systems Inc. Modified two-component gelation systems, methods of use and methods of manufacture
US9005672B2 (en) 2006-11-17 2015-04-14 Abbott Cardiovascular Systems Inc. Methods of modifying myocardial infarction expansion
US8192760B2 (en) 2006-12-04 2012-06-05 Abbott Cardiovascular Systems Inc. Methods and compositions for treating tissue using silk proteins
US8076295B2 (en) 2007-04-17 2011-12-13 Nanotope, Inc. Peptide amphiphiles having improved solubility and methods of using same
US11969501B2 (en) 2008-04-21 2024-04-30 Dompé Farmaceutici S.P.A. Auris formulations for treating otic diseases and conditions
WO2009132050A2 (en) 2008-04-21 2009-10-29 Otonomy, Inc. Auris formulations for treating otic diseases and conditions
US8496957B2 (en) 2008-07-21 2013-07-30 Otonomy, Inc Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
US9248159B2 (en) 2008-10-14 2016-02-02 Robert Stanley Berman MRSA bactericidal topical gel
KR101101321B1 (ko) * 2008-11-03 2012-01-02 주식회사 엠씨티티 상처 치유를 위한 하이드로 겔 형태의 세포전달용 비히클 및 그 제조방법
KR101163171B1 (ko) * 2009-01-20 2012-07-19 (주)케어젠 노긴?유래 펩타이드 및 그의 용도
EP2419116A1 (de) 2009-04-13 2012-02-22 North Western University Neue peptidbasierte gerüste für knorpelregenerierung und anwendungsverfahren dafür
PL2970422T3 (pl) 2013-03-15 2018-09-28 F.Hoffmann-La Roche Ag Polipeptydy IL-22 i białka fuzyjne IL-22 Fc i sposoby zastosowania
WO2015088990A1 (en) 2013-12-09 2015-06-18 Durect Corporation Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same
CA2997786A1 (en) * 2015-09-22 2017-03-30 MiRagen Therapeutics, Inc. Mir-19 modulators and uses thereof
GB2591709B (en) * 2015-12-04 2021-11-03 Harvard College Devices, methods, and compositions for restricting cell position and stabilizing cells in culture systems
PL3743088T3 (pl) 2018-01-26 2023-03-20 F. Hoffmann-La Roche Ag Kompozycje i sposoby stosowania il-22 fc
CN111655717A (zh) 2018-01-26 2020-09-11 豪夫迈·罗氏有限公司 IL-22 Fc融合蛋白及使用方法
CA3091139A1 (en) 2018-02-21 2019-08-29 Genentech, Inc. Dosing for treatment with il-22 fc fusion proteins

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4100271A (en) 1976-02-26 1978-07-11 Cooper Laboratories, Inc. Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes
US5705485A (en) * 1987-09-18 1998-01-06 Ethicon, Inc. Gel formulations containing growth factors
US5457093A (en) 1987-09-18 1995-10-10 Ethicon, Inc. Gel formulations containing growth factors
NZ226171A (en) * 1987-09-18 1990-06-26 Ethicon Inc Gel formulation containing polypeptide growth factor
US5100668A (en) * 1988-06-14 1992-03-31 Massachusetts Institute Of Technology Controlled release systems containing heparin and growth factors
US5013769A (en) * 1988-08-22 1991-05-07 Medipro Sciences Limited Method of making a hydrogel-forming wound dressing or skin coating material
US5470829A (en) 1988-11-17 1995-11-28 Prisell; Per Pharmaceutical preparation
FR2644066B1 (fr) 1989-03-09 1994-05-13 Therapeutiques Substitutives Compositions stabilisees comprenant des fgfs, leur procede d'obtention et leurs applications therapeutiques, chirurgicales et cosmetologiques
US5271943A (en) * 1989-10-27 1993-12-21 Scott Health Care Wound gel compositions containing sodium chloride and method of using them
US5591709A (en) * 1991-08-30 1997-01-07 Life Medical Sciences, Inc. Compositions and methods for treating wounds
EP0551626A1 (de) 1991-12-19 1993-07-21 LEK, tovarna farmacevtskih in kemicnih izdelkov, d.d. Thermoreversible Gel als pharmazeutische Grundmasse für eine galenische Form
US5952006A (en) * 1995-09-29 1999-09-14 L.A.M. Pharmaceuticals, Llc Drug preparations for treating impotency
FR2740678B1 (fr) * 1995-11-06 1999-05-14 Oreal Utilisation en cosmetique d'une composition solide ayant une matrice gelifiee et compositions cosmetiques ou dermatologiques mises en oeuvre
DE69735622T2 (de) * 1996-08-16 2007-04-12 MCW Research Foundation, Inc., Milwaukee Knochen morphogenetisches protein und fibroblasten wachstumsfaktor enthaltende zusammensetzungen und methoden zur induzierung der kardiogenese
US6103266A (en) * 1998-04-22 2000-08-15 Tapolsky; Gilles H. Pharmaceutical gel preparation applicable to mucosal surfaces and body tissues

Also Published As

Publication number Publication date
CA2341410A1 (en) 2000-03-16
JP2011021045A (ja) 2011-02-03
ES2288024T3 (es) 2007-12-16
WO2000013710A3 (en) 2000-06-02
IL141688A0 (en) 2002-03-10
EP1107791B8 (de) 2007-11-07
WO2000013710A2 (en) 2000-03-16
AU5909599A (en) 2000-03-27
PT1107791E (pt) 2007-07-06
CA2341410C (en) 2007-11-20
EP1107791A2 (de) 2001-06-20
JP5576772B2 (ja) 2014-08-20
DK1107791T3 (da) 2007-09-03
EP1107791B1 (de) 2007-05-30
IL141688A (en) 2006-07-05
DE69936212T2 (de) 2008-01-24
DE69936212D1 (de) 2007-07-12
CY1107704T1 (el) 2013-04-18
US6331309B1 (en) 2001-12-18
AU758178B2 (en) 2003-03-20
JP2002524425A (ja) 2002-08-06

Similar Documents

Publication Publication Date Title
DE69936212D1 (de) Hydrogelzusammensetzungen mit kontrollierter freigabe von wachstumsfaktoren
DE69930763D1 (en) Tgf-g beta inhibitor-peptide
FR2752582B1 (fr) Compositions a base de polyorganosiloxanes a groupements fonctionnels reticulables et leur utilisation pour la realisation de revetements anti-adherents
FR2712812B1 (fr) Composition pour la production de produits thérapeutiques in vivo.
MY133022A (en) Thermoplastic silicone-containing hyrogels
EP0871435A4 (de) Drei verschiedene polymertypen enthaltende formulierung mit verzögerter freigabe
WO2002039948A3 (en) Cross-linked hyaluronic acid-laminin gels and use thereof in cell culture and medical implants
WO2001044838A3 (en) Hybrid refractive birefringent multifocal ophthalmic lenses
MY118538A (en) Polymeric compositions and their production and uses
DE69524398D1 (de) Flüssige mittel zur wirkstoffabgabe
ATE501740T1 (de) Saugfähiger artikel mit einem beschichteten wasserquellbaren material
BR0014417A (pt) Processo para preparação de uma mistura polimérica dispersada em água, mistura polimérica dispersada em água, composição para preparação de um revestimento resistente à água, e, artigo revestido resistente à água
EP0990443A3 (de) Medizinische Zusammensetzungen
AU7713698A (en) Cross-slope level control for mobile machinery
CA2348495A1 (en) Intraocular lenses made from polymeric compositions
MXPA04002554A (es) Metodos y aparatos para revestir superficies para reducir la adsorcion de proteinas y la adhesion celular y presentar ligandos.
AU6789496A (en) Use as antifreeze of polymers with recurring succinyl units
DK0562445T3 (da) Gel, især oftalmisk
EP0663208A3 (de) Kombinierten Polymere zur Verwendung in künstlicher Tränenflussigkeit.
PL344518A1 (en) Polymer compositions
GB9828446D0 (en) Coating composition
GB2396617B (en) Polymeric materials
ATE233555T1 (de) In vivo polymerisierbare ophthalmische zusammenstellungen
EP0822209A3 (de) Kunststofffolien für Prothesen
PT991371E (pt) Método para tratar dentaduras

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1107791

Country of ref document: EP